RCM
CRL icon

Rivermont Capital Management’s Charles River Laboratories CRL Stock Holding History

Rivermont Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,565
Closed -$3.95M – 21
2023
Q1 		$3.95M Buy
+19,565
New +$4.43M 2.17% 19

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Rivermont Capital Management's CRL Position: Q2 2023 in Review

Rivermont Capital Management sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 19,565 shares — an estimated $3.95M sold.

Rivermont Capital Management first reported a position in CRL in Q1 2023 and held it in 1 quarter. The position peaked at $3.95M in Q1 2023. 613 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Rivermont Capital Management reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Rivermont Capital Management sold 19,565 Charles River Laboratories shares in Q2 2023, an estimated $3.95M.
  • Rivermont Capital Management first reported a position in Charles River Laboratories in Q1 2023 and held it in 1 quarter.
  • Rivermont Capital Management's Charles River Laboratories position peaked at $3.95M in Q1 2023.
  • 613 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Rivermont Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.